🚨 THE MOREPEN CDMO STORY MAY BE BIGGER THAN IT LOOKS 👀
API business is largely volume-driven.
CDMO can offer:
☑ Higher-value manufacturing
☑ Better margin potential
☑ Long-term customer relationships
☑ Better revenue visibility
☑ Operating leverage as capacity scales
Now look at Morepen Laboratories 👇
💰 ₹825 Cr multi-year global CDMO mandate
🌍 Customer: Leading global pharma major
📦 ₹50 Cr first commercial dispatch already completed
📈 ~₹225 Cr additional supplies expected in Q2 FY27
🏭 Reactor capacity being scaled from ~500 KL → 600 KL → 800 KL+
The BIG thesis:
If CDMO becomes a larger part of Morepen’s revenue mix, blended margins and earnings could potentially improve.
More CDMO → Better mix → Operating leverage → Higher EBITDA → Potentially higher valuation.
This is why I’m watching MOREPENLAB closely. 🔍📈
Not a recommendation. Do your own research.
September 8, 2026 1.7K 2
